IP Library Granted Patent US 8,211,449
Granted Patent B2
US 8,211,449 · App. 10/875,470 · Granted Jul 3, 2012

Pharmaceutically elegant, topical anhydrous aerosol foam

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,211,449
App. No.
10/875,470
Granted
Jul 3, 2012
Kind
B2
Abstract

A topical pharmaceutical aerosol foam containing liquid silicones to enhance cosmetic elegance. Although liquid silicones are inherent defoamers, a high quality, stable foam is produced.

Claims (17)

1. An anhydrous, topical pharmaceutical aerosol foam composition, comprising in pharmaceutically-elegant and effective amounts:

a lipophilic compound comprising petrolatum;

cyclomethicone;

3 to 7% by weight of the total composition of a foaming agent consisting of mono-, di-, or tri-esters of sorbitol or combinations thereof selected from the group consisting of sorbitan caprylate, sorbitan diisostearate, sorbitan dioleate, sorbitan isostearate, sorbitan laurate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, and combinations thereof;

a topically active pharmaceutical; and

a propellant,

wherein the composition is comprised in an aerosol container, and

wherein the amount of cyclomethicone ranges from about 5% to about 35% by weight of the total anhydrous, topical pharmaceutical aerosol foam composition.

2. The composition of claim 1 wherein the foaming agent is sorbitan monooleate.

3. The composition of claim 1 further comprising a rheology modifier.

4. The composition of claim 3 wherein the rheology modifier is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, beeswax, paraffin wax, and combinations thereof.

5. The composition of claim 1 wherein the topically active pharmaceutical is selected from the group consisting of acne actives, analgesics, anesthetics, anorectics, antihistamines, anti-inflammatory agents, antibiotics, antifungals, antivirals, antimicrobials, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatics, antiseborrheics, astringents, biologically active proteins and peptides, burn actives, cauterizing agents, depigmenting agents, diaper rash agents, enzymes, hair growth actives, hemostatics, keratolytics, canker sore actives, cold sore actives, dental actives, saliva actives, photosensitizing actives, skin protectant/barrier agents, steroids, sunburn actives, sunscreens, vaginal actives, wart actives, wound care actives; and retinol, retinoic acid and retinoic acid derivatives.

6. The composition of claim 1 wherein the propellant is a hydrocarbon.

7. The composition of claim 1 wherein the propellant is a hydrofluorocarbon.

8. The composition of claim 6 wherein the hydrocarbon is selected from the group consisting of butane, isomers of butane, propane, isomers of propane, pentane, isomers of pentane, and combinations thereof.

9. The composition of claim 7 wherein the hydrofluorocarbon is selected from the group consisting of 1,1,1,2 tetrafluoroethane and 1,1,1,2,3,3,3 heptafluoropropane.

10. The composition of claim 1 wherein the amount of lipophilic compound ranges from about 1% to about 80% by weight of the total anhydrous, topical pharmaceutical aerosol foam composition.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jun 16, 2016
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR IN INTEREST TO GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: RENAISSANCE SSP HOLDINGS, INC.; RENAISSANCE PHARMA (U.S.) HOLDINGS, INC.; RENAISSANCE PHARMA, INC.; PRESTIUM PHARMA, INC.; DPT LAKEWOOD, LLC; DPT LABORATORIES, LTD.; RENAISSANCE ACQUISITION HOLDINGS, LLC; RENAISSANCE DPT PARTNER SUB, LLC; DELCOR ASSET CORPORATION; DENCO ASSET, LLC
Reel/Frame 038930/0777 →
RELEASE OF SECURITY INTEREST Recorded Jun 13, 2016
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: DPT LABORATORIES, LTD.
Reel/Frame 038900/0365 →
SECURITY INTEREST Recorded Nov 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037111/0389 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR'S NAME FROM --BAVESH-- TO --BHAVESH-- PREVIOUSLY RECORDED ON REEL 019172 FRAME 0917. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE AND INTEREST. Recorded May 29, 2007
From: AUST, DUNCAN T; JONES, DAVID P; SHAH, BHAVESH P
To: DPT LABORATORIES, LTD.
Reel/Frame 019352/0032 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FILING DATE FROM --06/25/2004-- TO --06/24/2004-- PREVIOUSLY RECORDED ON REEL 015030 FRAME 0380. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE RIGHT, TITLE, AND INTEREST. Recorded Apr 17, 2007
From: AUST, DUNCAN T; JONES, DAVID P; SHAH, BAVESH P
To: DPT LABORATORIES, LTD.
Reel/Frame 019172/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2004
From: AUST, DUNCAN T.; JONES, DAVID P.; SHAH, BHAVESH P.
To: DPT LABORATORIES, LTD.
Reel/Frame 015030/0380 →
SECURITY AGREEMENT Recorded Aug 10, 2004
From: DPT LABORATORIES, LTD.
To: BANK OF AMERICA, N,A.
Reel/Frame 015057/0831 →